Clinical Trials Logo

Microtia clinical trials

View clinical trials related to Microtia.

Filter by:

NCT ID: NCT06394687 Not yet recruiting - Nutrition Clinical Trials

The Digestion of Protein Powders in Healthy Participants Using SIMBA and LIMBA Capsule

Start date: June 10, 2024
Phase: N/A
Study type: Interventional

This study aims to understand how the Milk Protein Concentrate/Fast Protein (MCP/FP) investigational product (IP) compares to a control the Micellar Casein Isolate/Slow Protein (MCI/SP) product in healthy volunteers. It involves two phases where participants will try both products. The main goal is to measure the type and rate of amino acids quickly in the small intestine after consuming the protein products and how this relates to gastric emptying.

NCT ID: NCT06289283 Active, not recruiting - Clinical trials for Urinary Bladder Neoplasms

Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder

Cancer bladder
Start date: October 12, 2023
Phase:
Study type: Observational

Microbes inhabiting the urinary tract that are playing an important role in maintenance of health and the development of diseases and bladder cancer. There is correlation between initiation of bladder cancer and microbes. Urine and bladder tissues from healthy individuals and patients with bladder cancer were analyzed using 16S rRNA sequencing, results show abundant phylum. Next-generation sequencing technologies will be applied with whole genomic and 16S ribosomal RNA gene sequencing for microbiota profiling in urine and bladder tissue of male healthy individuals and patients with bladder cancer. Results will lead to prevention, diagnosis and new treatment strategies for bladder cancer.

NCT ID: NCT06225336 Enrolling by invitation - Microtia Clinical Trials

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia)

AUR-201
Start date: November 4, 2022
Phase: Phase 1
Study type: Interventional

AUR-201 is indicated for the treatment of Grade II, III, or IV unilateral microtia in patients 8 to 29 years of age.

NCT ID: NCT06220994 Enrolling by invitation - Microtia Clinical Trials

the Gut Microbiome and Metabolomics in Chronic Lower extreMities Threatening Ischemia

MMM
Start date: November 15, 2021
Phase:
Study type: Observational [Patient Registry]

Intestinal floras and their metabolites are involved in progressing metabolic and cardiovascular diseases. However, currently, articles related to the relationship between intestinal floras and atherosclerosis mainly focus on coronary atherosclerotic disease (CAD) population, or atherosclerosis model animals such as ApoE-/-, LDLR-/- high-fat diet mice, and there are few studies on Chronic limb-threatening ischemia (CLTI). CLTI and CAD have a similar pathological basis of atherosclerosis. It is unclear whether intestinal flora plays an essential role in the occurrence and development of CLTI. This project aims to explore the relation between microorganisms, metabolites, and CLTI.

NCT ID: NCT06087874 Recruiting - Pregnancy Related Clinical Trials

Preventive Effect of Perinatal Oral Probiotic Supplementation (POPS) on Neonatal Jaundice

Start date: March 23, 2024
Phase: Phase 2
Study type: Interventional

This is a randomized double-blind placebo-controlled parallel group superiority clinical trial among 94 pregnant women (47 in each group) to investigate the effect of maternal perinatal probiotic supplementation on neonatal jaundice, breast milk microbiome, maternal stool, and infant fecal microbiome. Vivomixx®-probiotic product will be used as treatment and placebo as a control.

NCT ID: NCT06078566 Recruiting - Microtia Clinical Trials

Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201

AUR-201
Start date: January 26, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Long-term follow-up of unilateral microtia patients implanted with AUR-201.

NCT ID: NCT06072040 Recruiting - Microtia Clinical Trials

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia

AUR-201
Start date: January 26, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

AUR-201 is indicated for the treatment of Grade II, III, or IV unilateral microtia in patients 8 to 29 years of age.

NCT ID: NCT05963659 Recruiting - Alcohol Dependence Clinical Trials

Nitrate Modulates Cognitive Impairment Via Oral Microbiota.

Start date: September 10, 2023
Phase: N/A
Study type: Interventional

Alcohol use is increasingly prevalent in modern society and is known to cause cognitive impairment and dysregulation of inflammatory responses. In the present study, the investigators want to perform a randomised controlled trials to test whether nitrate could change the oral microbiota and benefit the cognitive impairment in alcohol dependence patients. The investigators survey the oral bacterial communities in saliva samples of 70 alcohol dependent patients following 14 days of dietary inorganic nitrate (nitrate-rich beetroot juice, ~750 mg NO3- /d) and placebo (nitrate-depleted beetroot juice, ~1 mg NO3- /d) supplementation.

NCT ID: NCT05929976 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort

NICHE
Start date: October 26, 2022
Phase:
Study type: Observational

Nutritional status is a measurable and modifiable factor that is often not considered during treatment and its clinical impact undervalued due in part to the heavy demands on clinicians in low and middle income countries to deliver therapy to large numbers of patients. The proposed study will create a biobank of clinical data and biological specimens which will foster future studies on cancer progression and prognosis as well as toxicities during treatment which may impact survivorship and late-effects. Eligible patients must be between 3 years and 18 years of age at time of assent/consent, have newly diagnosed B- or T-cell acute lymphoblastic leukemia or mixed phenotype acute leukemia confirmed by pathology report, and must be receiving treatment at one of the participating centers. Patients receiving hematopoietic cell transplant will be excluded. Institutions were selected to ensure representation of several global health indicators related to nutritional status and wealth classification according to the World Bank. Data related to demographic variables (socioeconomic status, food security), lifestyle habits (diet, physical activity), nutritional anthropometrics (height, weight and arm anthropometry), and nutritional biological indices (stool and blood) will be collected at designated timepoints throughout treatment and one year after the end of treatment.

NCT ID: NCT05714566 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Research on Gut Microbiome and Metabolomics Alterations in C.Difficile Infected IBD Patients

Start date: November 7, 2022
Phase:
Study type: Observational [Patient Registry]

The goal of this research is to compare alterations of gut microbiota and fecal metabolomics alterations between inflammatory bowel disease patients infected with or without Clostridioides difficile. The main questions it aim to answer are: which bacterial genus or fecal metabolites can discriminate IBD patients infected or more likely to be infected with Clostridioides difficile and their role in the pathogenesis of Clostridioides difficile. type of study: observational study participant population/health conditions 1. population diagnosed with Ulcerative colitis or Crohn's disease 2. Having diarrhea Participants will be included in this research. If there is a comparison group: Researchers will compare healthy people without IBD or any diarrhea to see if disease or diarrhea would affect the gut microbiota and metabolites.